At the UBS Global Life Sciences Conference held in New York this week, major proteomics instrument vendors emphasized platform integration, mark-eting their products to non-techie biologists, and carving out new niches in the proteomics market as key strategies in the coming quarters. Nearly all also expressed optimism that big pharma is once again opening its pocketbook.

Agilent

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.